Cargando…
Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy
Cardiac shock wave therapy (CSWT) is a novel therapeutic procedure for patients with angina that is refractory to conventional therapy. We investigated the potential mechanism and therapeutic efficacy of non-R-wave-triggered CSWT to attenuate myocardial dysfunction in a large animal model of hyperte...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654370/ https://www.ncbi.nlm.nih.gov/pubmed/36362064 http://dx.doi.org/10.3390/ijms232113274 |
_version_ | 1784828914181341184 |
---|---|
author | Li, Fei Zhen, Zhe Sun, Si-Jia Jiang, Yu Liang, Wei-Hao Belau, Markus Storz, Rafael Liao, Song-Yan Tse, Hung-Fat |
author_facet | Li, Fei Zhen, Zhe Sun, Si-Jia Jiang, Yu Liang, Wei-Hao Belau, Markus Storz, Rafael Liao, Song-Yan Tse, Hung-Fat |
author_sort | Li, Fei |
collection | PubMed |
description | Cardiac shock wave therapy (CSWT) is a novel therapeutic procedure for patients with angina that is refractory to conventional therapy. We investigated the potential mechanism and therapeutic efficacy of non-R-wave-triggered CSWT to attenuate myocardial dysfunction in a large animal model of hypertensive cardiomyopathy. Sustained elevated blood pressure (BP) was induced in adult pigs using a combination of angiotensin-II and deoxycorticosterone acetate (DOCA). Two sessions of non-R-wave-triggered CSWT were performed at 11 and 16 weeks. At 10 weeks, systolic and diastolic blood pressure, LV posterior wall thickness and intraventricular septum thickness significantly increased in both the hypertension and CSWT groups. At 20 weeks, +dP/dt and end-systolic pressure-volume relationship (ESPVR) decreased significantly in the hypertension group but not the CSWT group, as compared with week 10. A significant improvement in end-diastolic pressure-volume relationship (EDPVR) was observed in the CSWT group. The CSWT group exhibited significantly increased microvascular density and vascular endothelial growth factor (VEGF) expression in the myocardium. Cytokine array demonstrated that the CSWT group had significantly reduced inflammation compared with the hypertension group. Our results demonstrate that non-R-wave-triggered CSWT is safe and can attenuate LV systolic and diastolic dysfunction via enhancement of myocardial neovascularization and anti-inflammatory effect in a large animal model of hypertensive cardiomyopathy. |
format | Online Article Text |
id | pubmed-9654370 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96543702022-11-15 Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy Li, Fei Zhen, Zhe Sun, Si-Jia Jiang, Yu Liang, Wei-Hao Belau, Markus Storz, Rafael Liao, Song-Yan Tse, Hung-Fat Int J Mol Sci Article Cardiac shock wave therapy (CSWT) is a novel therapeutic procedure for patients with angina that is refractory to conventional therapy. We investigated the potential mechanism and therapeutic efficacy of non-R-wave-triggered CSWT to attenuate myocardial dysfunction in a large animal model of hypertensive cardiomyopathy. Sustained elevated blood pressure (BP) was induced in adult pigs using a combination of angiotensin-II and deoxycorticosterone acetate (DOCA). Two sessions of non-R-wave-triggered CSWT were performed at 11 and 16 weeks. At 10 weeks, systolic and diastolic blood pressure, LV posterior wall thickness and intraventricular septum thickness significantly increased in both the hypertension and CSWT groups. At 20 weeks, +dP/dt and end-systolic pressure-volume relationship (ESPVR) decreased significantly in the hypertension group but not the CSWT group, as compared with week 10. A significant improvement in end-diastolic pressure-volume relationship (EDPVR) was observed in the CSWT group. The CSWT group exhibited significantly increased microvascular density and vascular endothelial growth factor (VEGF) expression in the myocardium. Cytokine array demonstrated that the CSWT group had significantly reduced inflammation compared with the hypertension group. Our results demonstrate that non-R-wave-triggered CSWT is safe and can attenuate LV systolic and diastolic dysfunction via enhancement of myocardial neovascularization and anti-inflammatory effect in a large animal model of hypertensive cardiomyopathy. MDPI 2022-10-31 /pmc/articles/PMC9654370/ /pubmed/36362064 http://dx.doi.org/10.3390/ijms232113274 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Li, Fei Zhen, Zhe Sun, Si-Jia Jiang, Yu Liang, Wei-Hao Belau, Markus Storz, Rafael Liao, Song-Yan Tse, Hung-Fat Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy |
title | Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy |
title_full | Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy |
title_fullStr | Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy |
title_full_unstemmed | Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy |
title_short | Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy |
title_sort | attenuation of myocardial dysfunction in hypertensive cardiomyopathy using non-r-wave-synchronized cardiac shock wave therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654370/ https://www.ncbi.nlm.nih.gov/pubmed/36362064 http://dx.doi.org/10.3390/ijms232113274 |
work_keys_str_mv | AT lifei attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy AT zhenzhe attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy AT sunsijia attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy AT jiangyu attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy AT liangweihao attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy AT belaumarkus attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy AT storzrafael attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy AT liaosongyan attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy AT tsehungfat attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy |